Acquisition by Androski Lindsay of 310422 shares of Arbutus Biopharma at 3.2 subject to Rule 16b-3
| ABUS Stock | USD 3.50 0.23 7.03% |
Slightly above 63% of all Arbutus Biopharma's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Arbutus Biopharma Corp suggests that some traders are interested. Arbutus Biopharma's investing sentiment can be driven by a variety of factors including economic data, Arbutus Biopharma's earnings reports, geopolitical events, and overall market trends.
Arbutus |
Filed transaction by Arbutus Biopharma Corp Director, Officer: President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Arbutus Biopharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Arbutus Biopharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Arbutus Biopharma Maximum Pain Price Across June 20th 2025 Option Contracts
Arbutus Biopharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Arbutus Biopharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Arbutus Biopharma's options.
Arbutus Biopharma Fundamental Analysis
We analyze Arbutus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Arbutus Biopharma is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Arbutus Biopharma Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arbutus Biopharma stock to make a market-neutral strategy. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics with similar companies.
Peers
Arbutus Biopharma Related Equities
| CRVS | Corvus Pharmaceuticals | 0.30 | ||||
| ADMA | ADMA Biologics | 0.1 | ||||
| AFMD | Affimed NV | 3.70 | ||||
| ADAP | Adaptimmune Therapeutics | 4.55 |
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.